retatrutide type 2 diabetes phase 2 weight loss 2024 Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released trial results demonstrating 25% in half of people with #obesity. This amount of weight loss has not been accomplished VisualAbstract: Retatrutide reduces body weight

Evidence now shows that consistent weight loss occurs when GLP-1 therapy continues, with weight regain beginning 3 to 6 months after discontinuationunderscoring the importance of ongoing treatment strategies

Pharmaceuticals (Basel) 18(5):614 Verma M, Lizama BN, Chu CT (2022) Excitotoxicity, calcium and mitochondria: a triad in synaptic neurodegeneration

Retatrutide 20mg Pen sits within this wider research category as a product format

however, this was ultimately aborted after she developed ventriculitis due to colonization with Propionibacterium acnes

64% female

In contrast, Ozempic is specifically approved for the treatment of type 2 diabetes